查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1886319

肺炎治療市場－全球產業規模、佔有率、趨勢、機會和預測，按感染類型、類型、藥物類別、最終用戶、地區和競爭格局分類，2020-2030年預測

Pneumonia Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Infection Type, By Type, By Drug Class, By End User, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肺炎治療藥物市場規模將從2024年的29.1億美元成長到2030年的45.6億美元，複合年成長率達7.76%。肺炎治療藥物涵蓋一系列旨在對抗肺炎的藥物介入和醫療手段。肺炎是一種嚴重的呼吸道感染，其特徵是肺部氣囊發炎。全球市場擴張的主要驅動力是呼吸系統疾病持續高發，尤其是在老年人和幼兒等易感人群中。

市場概覽
預測期 2026-2030
市場規模：2024年 29.1億美元
市場規模：2030年 45.6億美元
複合年成長率：2025-2030年 7.76%
成長最快的細分市場 社區型肺炎 [CAP]
最大的市場 北美洲

主要市場促進因素

全球肺炎治療市場的主要驅動力是全球肺炎發病率的不斷上升以及抗生素抗藥性威脅的日益加劇。全球肺炎高發生率持續居高不下，導致患者群體不斷擴大，需要從初始抗菌治療到支持性護理等各種治療干預措施。

主要市場挑戰

新型廣譜抗生素和抗病毒藥物所需的大量資金投入和嚴格的法規核准流程，嚴重阻礙了全球肺炎治療市場的成長。從最初的研發到產品上市，漫長而複雜的過程需要大量資金，這可能會阻礙潛在的創新者，並降低製藥公司投資這一關鍵領域的動機。

主要市場趨勢

單株抗體和宿主導向療法等新型治療手段的出現，代表著全球肺炎治療市場的顯著成長趨勢。這些創新療法突破了傳統抗生素的限制，提供了對抗感染的新機制，並有助於應對抗菌素抗藥性這一迫切挑戰。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：客戶之聲

第5章：全球肺炎治療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依感染類型（院內獲得性肺炎[HAP]、社區型肺炎[CAP]、呼吸器相關性肺炎[VAP]）
    • 依類型（藥物、預防性疫苗、氧氣治療）
    • 依藥物類別（抗菌藥物、抗病毒藥物、抗真菌藥物）
    • 按最終使用者（醫院和診所、門診手術中心、其他）
    • 按地區
    • 按公司（2024 年）
  • 市場地圖

第6章：北美肺炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肺炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肺炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肺炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肺炎治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球肺炎治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • Pfizer Inc.
  • AstraZeneca Plc.
  • Eli Lilly & company
  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 22375

The Global Pneumonia Therapeutics Market will grow from USD 2.91 Billion in 2024 to USD 4.56 Billion by 2030 at a 7.76% CAGR. Pneumonia therapeutics comprise a class of pharmaceutical interventions and medical treatments aimed at combating pneumonia, a serious respiratory infection characterized by inflammation of the lung's air sacs. The global market's expansion is fundamentally propelled by the persistent high global incidence of respiratory illnesses, particularly among susceptible demographics such as the elderly and young children.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.91 Billion
Market Size 2030USD 4.56 Billion
CAGR 2025-20307.76%
Fastest Growing SegmentCommunity-Acquired Pneumonia [CAP]
Largest MarketNorth America

Key Market Drivers

The global pneumonia therapeutics market is significantly driven by the increasing worldwide incidence of pneumonia and the escalating threat of antibiotic resistance. The persistent high global incidence of pneumonia creates a continuous and expanding patient population requiring various therapeutic interventions, from initial antimicrobial treatments to supportive care. This rising burden necessitates robust market supply and fosters demand for improved treatment efficacy and accessibility across diverse demographics.

Key Market Challenges

The substantial financial investment and stringent regulatory approval processes for new broad-spectrum antibiotics and antiviral treatments pose a significant impediment to the growth of the global pneumonia therapeutics market. The lengthy and complex journey from initial research to market entry demands considerable capital, which can deter potential innovators and reduce the incentive for pharmaceutical companies to invest in this critical area. This is particularly relevant for novel agents, where the inherent risk of failure is high, and the return on investment can be uncertain due to evolving pathogen resistance and specific treatment protocols aimed at preserving drug efficacy.

Key Market Trends

The emergence of novel therapeutic classes, such as monoclonal antibodies and host-directed therapies, represents a significant growth trend in the global pneumonia therapeutics market. These innovative treatments move beyond traditional antibiotics, offering new mechanisms to combat infection and address the pressing challenge of antimicrobial resistance. Monoclonal antibodies provide targeted immune responses, while host-directed therapies modulate the body's own defense mechanisms, potentially leading to broader efficacy and reduced development of resistance.

Key Market Players

  • Pfizer Inc.
  • AstraZeneca Plc.
  • Eli Lilly & company
  • F. Hoffmann-La Roche Ltd.
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi SA
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma Limited

Report Scope:

In this report, the Global Pneumonia Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pneumonia Therapeutics Market, By Infection Type:

  • Hospital-acquired Pneumonia [HAP]
  • Community-acquired Pneumonia [CAP]
  • Ventilator-associated Pneumonia [VAP]

Pneumonia Therapeutics Market, By Type:

  • Drugs
  • Preventive Vaccines
  • Oxygen Therapy

Pneumonia Therapeutics Market, By Drug Class:

  • Antibacterial Drugs
  • Antiviral Drugs
  • Antifungal Drugs

Pneumonia Therapeutics Market, By End User:

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

Pneumonia Therapeutics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Pneumonia Therapeutics Market.

Available Customizations:

Global Pneumonia Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pneumonia Therapeutics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Infection Type (Hospital-acquired Pneumonia [HAP], Community-acquired Pneumonia [CAP], Ventilator-associated Pneumonia [VAP])
    • 5.2.2. By Type (Drugs, Preventive Vaccines, Oxygen Therapy)
    • 5.2.3. By Drug Class (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs)
    • 5.2.4. By End User (Hospitals and Clinics, Ambulatory Surgical Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Pneumonia Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Infection Type
    • 6.2.2. By Type
    • 6.2.3. By Drug Class
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pneumonia Therapeutics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Infection Type
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By Drug Class
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Pneumonia Therapeutics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Infection Type
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By Drug Class
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Pneumonia Therapeutics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Infection Type
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By Drug Class
        • 6.3.3.2.4. By End User

7. Europe Pneumonia Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Infection Type
    • 7.2.2. By Type
    • 7.2.3. By Drug Class
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pneumonia Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Infection Type
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By Drug Class
        • 7.3.1.2.4. By End User
    • 7.3.2. France Pneumonia Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Infection Type
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By Drug Class
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Pneumonia Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Infection Type
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By Drug Class
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Pneumonia Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Infection Type
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By Drug Class
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Pneumonia Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Infection Type
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By Drug Class
        • 7.3.5.2.4. By End User

8. Asia Pacific Pneumonia Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Infection Type
    • 8.2.2. By Type
    • 8.2.3. By Drug Class
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pneumonia Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Infection Type
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By Drug Class
        • 8.3.1.2.4. By End User
    • 8.3.2. India Pneumonia Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Infection Type
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By Drug Class
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Pneumonia Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Infection Type
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By Drug Class
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Pneumonia Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Infection Type
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By Drug Class
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Pneumonia Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Infection Type
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By Drug Class
        • 8.3.5.2.4. By End User

9. Middle East & Africa Pneumonia Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Infection Type
    • 9.2.2. By Type
    • 9.2.3. By Drug Class
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pneumonia Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Infection Type
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By Drug Class
        • 9.3.1.2.4. By End User
    • 9.3.2. UAE Pneumonia Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Infection Type
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By Drug Class
        • 9.3.2.2.4. By End User
    • 9.3.3. South Africa Pneumonia Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Infection Type
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By Drug Class
        • 9.3.3.2.4. By End User

10. South America Pneumonia Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Infection Type
    • 10.2.2. By Type
    • 10.2.3. By Drug Class
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pneumonia Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Infection Type
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By Drug Class
        • 10.3.1.2.4. By End User
    • 10.3.2. Colombia Pneumonia Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Infection Type
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By Drug Class
        • 10.3.2.2.4. By End User
    • 10.3.3. Argentina Pneumonia Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Infection Type
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By Drug Class
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pneumonia Therapeutics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Pfizer Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. AstraZeneca Plc.
  • 15.3. Eli Lilly & company
  • 15.4. F. Hoffmann-La Roche Ltd.
  • 15.5. Viatris Inc.
  • 15.6. Teva Pharmaceutical Industries Ltd.
  • 15.7. Sanofi SA
  • 15.8. Novartis AG
  • 15.9. Sun Pharmaceutical Industries Ltd.
  • 15.10. Aurobindo Pharma Limited

16. Strategic Recommendations

17. About Us & Disclaimer